{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/pyelonephritis-acute/","result":{"data":{"firstChapter":{"id":"02ed8486-e946-512b-82a2-668a9ff16030","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field d67fe6dd-f1e3-4417-a2bc-0bc851dabc95 --><h1>Pyelonephritis - acute: Summary</h1><!-- end field d67fe6dd-f1e3-4417-a2bc-0bc851dabc95 -->","htmlStringContent":"<!-- begin item 36e99adc-2c9b-4f69-a5a0-73b6b3e6cfbb --><!-- begin field cbe567b3-5f99-4f47-a16c-4834ab87969a --><ul><li>Acute pyelonephritis is an infection of one or both kidneys usually caused by bacteria travelling up from the bladder – the most common causative pathogen is Escherichia coli, which is responsible for 60-80% of uncomplicated infections.</li><li>Complications of acute pyelonephritis include:<ul><li>Sepsis.</li><li>Parenchyma renal scarring. </li><li>Recurrent urinary tract infections.</li><li>Renal abscess formation.</li><li>Preterm labour in pregnancy.</li><li>Emphysematous pyelonephritis.</li></ul></li><li>Acute pyelonephritis should be diagnosed by taking a detailed medical history and conducting a physical examination. </li><li>Acute pyelonephritis should be suspected in people with signs or symptoms of a urinary tract infection (for example, dysuria, frequency, urgency) accompanied by any new signs or symptoms of pyelonephritis (including fever, nausea, vomiting, or flank pain).</li><li>A midstream or catheter specimen of urine should be sent for culture and sensitivity.<ul><li>A urine dipstick test is not necessary, but may be a useful adjunct to guide diagnosis. However, it should not be used in people with an indwelling catheter, or aged over 65 years. </li></ul></li><li>A final diagnosis of acute pyelonephritis should be made in people with loin pain and/or fever if a UTI is confirmed by culturing a urinary pathogen from the urine, and other causes of loin pain and/or fever have been excluded.</li><li>People with severe symptoms, or signs or symptoms which suggest a more serious illness or condition should be admitted to hospital. </li><li>All other people should be offered an antibiotic. <ul><li>An antibiotic can be started once a midstream or catheter specimen of urine has been obtained for culture and sensitivity. </li><li>For women who are <em>not </em>pregnant, men, and people with an indwelling catheter – ciprofloxacin 500 mg twice a day for 7 days; trimethoprim 200mg twice a day for 14 days; co-amoxiclav 500/125 mg three times a day for 7-10 days; or cefalexin 500mg twice or three times a day (up to 1– 1.5g three or four times a day for severe infections) for 7-10 days should be prescribed.</li><li>For pregnant women who do <em>not </em>require admission — cefalexin 500mg twice or three times a day (up to 1– 1.5g three or four times a day for severe infections) for 7-10 days should be prescribed.</li></ul></li><li>The culture and sensitivity results should be reviewed when they become available, and the antibiotic changed if indicated. If the bacteria are resistant and symptoms are not already improving, a narrow-spectrum antibiotic should be used wherever possible. </li><li>Advice should be given about: <ul><li>Possible adverse effects of the antibiotic, particularly diarrhoea and nausea.</li><li>When to seek medical help — for example, if symptoms worsen at any time, do not start to improve within 48 hours of taking the antibiotic, or if they become systemically very unwell.</li><li>Using paracetamol for pain, or if preferred and suitable ibuprofen if required.</li><li>Drinking enough fluids to avoid dehydration.</li></ul></li><li>The person should be reassessed if symptoms worsen at any time, or they do not start to improve within 48 hours of starting the antibiotic.</li><li>Referral should be considered for people if they: <ul><li>Are significantly dehydrated or unable to take oral fluids and medicines.</li><li>Are pregnant.</li><li>Have a higher risk of developing complications — people with known or suspected structural or functional abnormality of the genitourinary tract or underlying disease (such as diabetes mellitus, or immunosuppression).</li><li>Have recurrent episodes of UTI (for example two or more episodes in a 6-month period).</li></ul></li><li>Referral should also be considered for:<ul><li>Men, following a single episode without an obvious cause. </li><li>Women with recurrent pyelonephritis. </li></ul></li><li>People suspected of having urological cancer should be referred urgently using a suspected cancer pathway for an appointment within 2 weeks.</li></ul><!-- end field cbe567b3-5f99-4f47-a16c-4834ab87969a --><!-- end item 36e99adc-2c9b-4f69-a5a0-73b6b3e6cfbb -->","topic":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51","topicId":"44207967-66bd-4750-aa84-8d9a53c85df0","topicName":"Pyelonephritis - acute","slug":"pyelonephritis-acute","aliases":[],"chapters":[{"id":"02ed8486-e946-512b-82a2-668a9ff16030","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"46426ef8-dbce-5314-8014-895736033f59","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes"},{"id":"ac7d383b-749f-5a71-b1a3-64b8ee85c6e4","slug":"update","fullItemName":"Update"}]},{"id":"d8333a3b-c658-5cb9-8d52-f4731cb7591a","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"82a178c6-fb1b-55a0-8fff-db47a9a4e56f","slug":"goals","fullItemName":"Goals"},{"id":"528ddc23-f69e-558e-a643-3efdf3ed0c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"251eeb06-8579-5cc4-8e1a-95f1d66519b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f66a975d-d6fb-5db8-9b28-8efc292c4f13","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b5e9e7df-f433-574c-9008-725e03502836","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0a10e02-7199-5bc4-858a-f5b264b68ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"86ae3b5d-e5ac-595b-9ce2-6bd39b36e14d","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"56a59908-ef99-57a5-94c0-91567fd0c3c3","slug":"definition","fullItemName":"Definition"},{"id":"ec53872e-9c88-566c-bda0-5c8be69f09ba","slug":"causes","fullItemName":"Causes"},{"id":"73f19a3b-6441-55c5-81ba-0912f3b42a15","slug":"complications","fullItemName":"Complications"},{"id":"17fd8038-ffd8-57e6-aa5e-f86def547e29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"4ca15553-84c0-5297-abd9-5141ab1dbec6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","slug":"management","fullItemName":"Management","subChapters":[{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"936e6198-43d8-5e72-be82-c2c59705ea07","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"bf21ee38-5a2a-5700-bfd5-24b5084b8cbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5d08cf27-dc02-5eea-b5c3-b6308f0d1374","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"11dfcefc-cdc3-5c3f-aeea-da5c0be2ebaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5cc5db18-4c4f-5e6e-9169-72968b0e3705","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7685686-568f-5174-afd7-a7778a4f2716","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51","topicId":"44207967-66bd-4750-aa84-8d9a53c85df0","topicName":"Pyelonephritis - acute","slug":"pyelonephritis-acute","aliases":[],"topicSummary":"Acute pyelonephritis is caused by infection within the renal pelvis, with or without active infection of the renal parenchyma.","lastRevised":"Last revised in November 2020","nextPlannedReviewBy":"2023-03-01T00:00:00+00:00","nextPlannedReviewByDateTime":"2023-03","nextPlannedReviewByDisplay":"March 2023","specialities":[{"id":"e174a859-759f-5b1d-898e-1a4155645e13","name":"Infections and infestations","slug":"infections-infestations"},{"id":"f72b3ad6-0501-5364-8469-e48bd9b988b9","name":"Kidney disease and urology","slug":"kidney-disease-urology"}],"chapters":[{"id":"02ed8486-e946-512b-82a2-668a9ff16030","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"46426ef8-dbce-5314-8014-895736033f59","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"e0c98a4b-654e-5b3d-acbe-7af83e06b09e","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"d957e39c-6b0e-5ab2-b109-25b3d89f2a69","slug":"changes","fullItemName":"Changes"},{"id":"ac7d383b-749f-5a71-b1a3-64b8ee85c6e4","slug":"update","fullItemName":"Update"}]},{"id":"d8333a3b-c658-5cb9-8d52-f4731cb7591a","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"82a178c6-fb1b-55a0-8fff-db47a9a4e56f","slug":"goals","fullItemName":"Goals"},{"id":"528ddc23-f69e-558e-a643-3efdf3ed0c46","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"251eeb06-8579-5cc4-8e1a-95f1d66519b7","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"f66a975d-d6fb-5db8-9b28-8efc292c4f13","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"b5e9e7df-f433-574c-9008-725e03502836","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"c0a10e02-7199-5bc4-858a-f5b264b68ca3","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"86ae3b5d-e5ac-595b-9ce2-6bd39b36e14d","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"56a59908-ef99-57a5-94c0-91567fd0c3c3","slug":"definition","fullItemName":"Definition"},{"id":"ec53872e-9c88-566c-bda0-5c8be69f09ba","slug":"causes","fullItemName":"Causes"},{"id":"73f19a3b-6441-55c5-81ba-0912f3b42a15","slug":"complications","fullItemName":"Complications"},{"id":"17fd8038-ffd8-57e6-aa5e-f86def547e29","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"235cbfdb-ded5-56f1-8b79-6e33631422d9","slug":"diagnosis","fullItemName":"Diagnosis","subChapters":[{"id":"4ca15553-84c0-5297-abd9-5141ab1dbec6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"ede39de9-ed86-5d54-8a0d-82bf548356a4","slug":"signs-symptoms","fullItemName":"Signs and symptoms"},{"id":"2c226c8f-c4ef-59ed-828e-590f38c1719c","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"3f5167b2-e2ea-5d21-93ef-3ed426750dea","slug":"management","fullItemName":"Management","subChapters":[{"id":"30a86df1-8159-5bcc-9187-aa647071eeab","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"db7647fb-c954-543c-ac60-d09f69832f7e","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"93430c57-39bc-5b8b-b176-44cccba23928","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"d385ea3c-fa24-5d51-8bf6-b1372c9fdf3c","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"f429e0c9-ab9b-5885-b171-ea841f15722e","slug":"cefalexin","fullItemName":"Cefalexin"},{"id":"df1e11c6-9e97-5899-b2b9-0eac5877ab4c","slug":"trimethoprim","fullItemName":"Trimethoprim"}]},{"id":"936e6198-43d8-5e72-be82-c2c59705ea07","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"2b045a54-20ef-5b6e-8003-81b3052b42a8","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"bf21ee38-5a2a-5700-bfd5-24b5084b8cbf","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"4a868f34-40b1-5196-97ec-2b8334024394","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"5d08cf27-dc02-5eea-b5c3-b6308f0d1374","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"11dfcefc-cdc3-5c3f-aeea-da5c0be2ebaa","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"5cc5db18-4c4f-5e6e-9169-72968b0e3705","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f7685686-568f-5174-afd7-a7778a4f2716","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"1ee909c1-6785-5b3a-a71f-c675db878f51"}},"staticQueryHashes":["3666801979"]}